Ascites - 119 Studies Found
| Terminated |
: Trial of Sunitinib for Refractory Malignant Ascites : Ascites : 2008-11-21 : Drug: Sunitinib Patients will be given Sunitinib 50 mg orally daily for four weeks, followed by a two we |
| Completed |
: Safety and Performance of the Automated Fluid Shunt in Patients With Ascites and Diuretic Resistance : Ascites : 2009-12-10 : Device: NovaShunt's Automated Fluid Shunt implantation The Automated Fluid Shunt (AFS) Device consists o |
| Terminated |
: Sodium Restriction in the Management of Cirrhotic Ascites : Ascites : 2007-10-22 :
|
| Recruiting |
: To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites : Ascites : 2015-12-05 :
|
| Terminated |
: An Early Safety and Efficacy Study of Ascites Management: Standard Paracentesis or Early Intervention With Pleurx Catheters in Patients With Malignant Ascites : Malignant Ascites : 2010-02-25 :
|
| Recruiting |
: Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology : Refractory Malignant Ascites : 2015-06-16 :
|
| Withdrawn |
: A Study of Bevacizumab to Prevent Malignant Ascites : Malignant Ascites : 2009-05-21 : Drug: Bevacizumab Bevacizumab is given as an IV infusion of 15 mg/kg every three weeks for 12 weeks. |
| Active, not recruiting |
: Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory Ascites : Ascites : 2010-08-24 : Behavioral: McGill Quality of Life Questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire |
| Recruiting |
: Symptomatic Ascites Drainage With a Patient-controlled Vascular Catheter. : Malignant Ascites : 2016-03-20 :
|
| Completed |
: Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites : Malignant Ascites : 2006-05-15 : Drug: catumaxomab Catumaxomab is administered intraperitoneally via an indwelling catheter (or port) as |